Active ingredients: Enalapril
Innovace 2.5 mg Tablets.
Innovace 5 mg Tablets.
Innovace 10 mg Tablets.
Innovace 20 mg Tablets.
Tablets.
| Strength | Appearance | Country |
|---|---|---|
| 2.5 mg | White, round shaped tablet, one side marked MSD 14, the other side plain | Germany, Ireland, Sweden, United Kingdom |
| 5 mg | White, rounded triangle shaped tablet, one side scored*, the other side marked MSD 712 | Austria, Finland, France, Germany, Ireland, Portugal, The Netherlands, Spain, Sweden, United Kingdom |
| White, round shaped tablet, one side scored*, the other side marked 712 | Italy | |
| White, round flat tablet, one side scored*, other side plain | Greece | |
| 10 mg | Rust Red, rounded triangle shaped tablet, one side scored*, the other side marked MSD 713 | Austria, Finland, Germany, Ireland, The Netherlands, Sweden, United Kingdom |
| 20 mg | Peach, rounded triangle shaped tablet, one side scored*, the other side marked MSD 714 | Austria, Belgium, Finland, France, Germany, Ireland, Luxembourg, Portugal, The Netherlands, Spain, Sweden, United Kingdom |
| Peach, round shaped tablet, one side scored quartersect*, the other side marked 714 | Italy | |
| Peach, round flat tablet, one side scored* other side plain | Greece |
* The scoreline is only to facilitate breaking for ease of swallowing and not to divide into equal doses.
Each tablet contains 2.5 mg of enalapril maleate.
Excipient: each tablet contains 99 mg of lactose monohydrate.
Each tablet contains 5 mg of enalapril maleate.
Excipient: each tablet contains 198 mg of lactose monohydrate.
Each tablet contains 10 mg of enalapril maleate.
Excipient: each tablet contains 164 mg of lactose monohydrate.
Each tablet contains 20 mg of enalapril maleate.
Excipient: each tablet contains 154 mg of lactose monohydrate.
Excipient(s) with known effect: For the full list of excipients, see section 6.1.
Enalapril is a derivative of two amino-acids, L-alanine and L-proline. After absorption, enalapril is hydrolysed to enalaprilat, which inhibits ACE. Inhibition of ACE results in decreased plasma angiotensin II, which leads to increased plasma renin activity (due to removal of negative feedback of renin release), and decreased aldosterone secretion.
Sodium hydrogen carbonate
Maize starch
Pregelatinised corn starch
Magnesium stearate
Lactose monohydrate
Iron oxide red (E172) – 10 mg and 20 mg tablets only
Iron oxide yellow (E172) – 20 mg tablet only
Innovace 2.5 mg: All-aluminium blister packages containing 2, 11, 20, 28, 30, 40, 49 × 1, 50, or 100 tablets.
Innovace 5 mg: All-aluminium blister packages containing 2, 14, 20, 28, 28 × 1, 30, 49 × 1, 50, 60, 98, or 100 tablets.
Innovace 10 mg: All-aluminium blister packages containing 28, 49 × 1, 30, 50, 98 or 100 tablets.
Innovace 20 mg: All-aluminium blister packages containing 10, 14, 20, 28, 28 × 1, 30, 49 × 1, 50, 56, 60, 84, 90, 98, 100 or 500 tablets.
Not all pack sizes may be marketed.
Merck Sharp & Dohme Limited, Hertford Road, Hoddesdon, Hertfordshire, EN11 9BU, UK
2.5 mg Tablet: PL 00025/0220
5 mg Tablet: PL 00025/0194
10 mg Tablet: PL 00025/0195
20 mg Tablet: PL 00025/0196
Date of first authorisation:
| 2.5 mg tablets | PL 00025/0220 | first licensed | 17 April 1986 |
| 5 mg tablets | PL 00025/0194 | first licensed | 06 December 1984 |
| 10 mg tablets | PL 00025/0195 | first licensed | 06 December 1984 |
| 20 mg tablets | PL 00025/0196 | first licensed | 06 December 1984 |
Date of latest renewal: 01 November 2009